Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of Bridion for reversal of neuromuscular blockade in high-risk surgical adults
2017-000187-15Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in neuromuscular block (NMB) (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of subjects with treatment-emergent sinus bradycardia. Started Aug 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2017-000187-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000187-15.